Botulinum toxin application

PreclinicalSmall molecule

AAbant Izzet Baysal University

Botulinum toxin application is one of 5 small molecule programs targeting Hemiplegia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HemiplegiaActive, not recruiting

HemiplegiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Hemiplegia

#DrugCompanyPhaseTrials

Dojolvi

Ultragenyx

Approved

—2

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Xyrem

Xylocaine

Botulinum toxin application

AAbant Izzet Baysal University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hemiplegia1 trial

Investigation of the Effects of Upper Extremity Botulinum Toxin Application on Forearm Muscle Thickness and Motor Recovery in Patients With Hemiplegia

Completed·—··NCT07083752·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Botulinum toxin application. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Botulinum toxin application compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Botulinum toxin application. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Abant Izzet Baysal University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAbant Izzet Baysal University

Botulinum toxin application

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hemiplegia1 trial

References

Drug Info

Quick Facts

Related News